Patent ID: 7622251
Filing Date: 2009-11-24
Classification: A61P,C12Q,G01N,G16B

Abstract:
1. A method comprising: measuring, in a tumor sample obtained from a patient with estrogen receptor (ESR1) positive (>10 fmol/mg cytosol protein) breast cancer, an ESR1 Group Score or ESR1, BCL2 and SCUBE2 RNA transcript expression levels; calculating a predictive score based on the ESR1 Group Score or expression levels of said RNA transcripts to determine the likelihood that said patient has an increased likelihood of a beneficial response to treatment with an anti-estrogen drug, wherein increases in the ESR1 Group Score, or in the expression levels of said RNA transcripts positively correlate with an increased likelihood of a beneficial response to said treatment, and generating a report based on the predictive score.